The US Food & Drug Administration has approved TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis in patients age 6 years and older who have at least one F508del mutation.  We will be working with famalies and insurance companies to get everyone access to this medication as soon as possible.  Please be patient as it can take some time for the insurance companies to catch up with the new indication.  

Ryan Thomas, MD

Assistant Professor of Pediatrics and Human Development

Director, MSU Cystic Fibrosis Center